sGC-cGMP signaling: target for anticancer therapy

Area of Science:

• Biochemistry
• Molecular Biology
• Cardiovascular Physiology

Background:

• The discovery of cyclic guanosine monophosphate (cGMP) and guanylyl cyclase activity in the 1960s laid the groundwork for understanding NO signaling.
• The Nobel Prize in Medicine or Physiology 1998 recognized the role of nitric oxide (NO) as a cardiovascular signaling molecule.
• Nitrate-containing compounds, like glyceryl trinitrate (nitroglycerin), have a long history in medicinal use for cardiovascular conditions.

Purpose of the Study:

• To review the role of soluble guanylyl cyclase (sGC)-cGMP signaling in cell proliferation.
• To introduce the targeting of sGC-cGMP signaling as a potential cancer therapy.
• To explore the involvement of sGC-cGMP signaling in the chromatin-microenvironment.

Main Methods:

• Review of existing literature on sGC-cGMP signaling pathways.
• Presentation of novel research targeting sGC-cGMP for cancer treatment.
• Investigation of sGC-cGMP's role in chromatin regulation and cellular processes.

Main Results:

• Soluble guanylyl cyclase (sGC) acts as the primary receptor for NO, with the α1β1 isoform being essential for catalytic activity.
• NO binding to sGC significantly enhances its activity, leading to a substantial increase in cGMP production (≥200-fold).
• Studies indicate a significant role for sGC-cGMP signaling in regulating cell proliferation and potentially influencing the tumor microenvironment.

Conclusions:

• The NO/cGMP pathway is a critical regulator in both physiological and pathological processes.
• Targeting the sGC-cGMP pathway presents a promising avenue for developing innovative cancer therapies.
• Further research into sGC-cGMP signaling in cell proliferation, cancer, and chromatin dynamics is warranted.